AIMLogo.jpg
Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees
10 mars 2014 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"or "Hemispherx"), announced that after more than a week in trial, a federal jury in Atlanta...